Visveswarapura Institute of Pharmaceutical Sciences, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Hematology and Oncology Department, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Med Life. 2022 Jun;15(6):835-844. doi: 10.25122/jml-2022-0085.
Tamoxifen is one of the most used drugs for breast cancer. This study aimed to investigate the effect of the Tamoxifen mechanism on the epithelial-mesenchymal transition (EMT) pathway among breast cancer patients due to its resistance to breast cancer cells. We selected the appropriate datasets from the GEO database using continuous and integrated bioinformatics analysis. We examined the signaling pathways, gene ontology, and protein association of genes after classifying the gene expression profile. Finally, we confirmed the candidate genes using the GEPIA database. Two groups were defined for gene expression profiles. The first group in which the expression profile of genes increased after Tamoxifen was evaluated using the expression profile of genes that decreased in the EMT pathway. The second group was the opposite of the first group. 253 genes in the first group and 302 genes in the second group were shared. The genes in the first group were involved in various pathways of cell death, focal adhesion, and cellular aging. The second group was more involved in different phases of the cell cycle. Finally, MYLK, SOCS3, and STAT5B proteins from the first group and BIRC5, PLK1, and RAPGAP1 proteins from the second group were selected as candidate proteins in connection with the effect of Tamoxifen on the EMT pathway. We evaluated Tamoxifen's effect on the EMT pathway more accurately. However, for a closer look at Tamoxifen, more studies need to be done on target genes and proteins to clarify their role.
他莫昔芬是乳腺癌最常用的药物之一。本研究旨在通过研究他莫昔芬作用于乳腺癌细胞耐药的机制，探讨其对乳腺癌上皮间质转化（EMT）通路的影响。我们使用连续和综合的生物信息学分析，从 GEO 数据库中选择合适的数据集。我们在对基因表达谱进行分类后，检查了信号通路、基因本体和蛋白质关联。最后，我们使用 GEPIA 数据库确认了候选基因。我们将基因表达谱分为两组。第一组评估的是在 EMT 通路中基因表达下调的情况下，他莫昔芬作用后基因表达谱上调的情况。第二组则与第一组相反。第一组有 253 个基因，第二组有 302 个基因。第一组的基因参与细胞死亡、黏附斑和细胞衰老等多种途径。第二组更多地参与细胞周期的不同阶段。最后，我们选择第一组中的 MYLK、SOCS3 和 STAT5B 蛋白以及第二组中的 BIRC5、PLK1 和 RAPGAP1 蛋白作为与他莫昔芬对 EMT 通路作用相关的候选蛋白。我们更准确地评估了他莫昔芬对 EMT 通路的影响。然而，为了更深入地了解他莫昔芬，需要对靶基因和蛋白进行更多的研究，以阐明它们的作用。
